Physical health monitoring of patients with schizophrenia.
暂无分享,去创建一个
John M Davis | Jeffrey A Lieberman | Nancy H. Covell | Alexander L. Miller | J. Lieberman | S. Stroup | J. Bigger | R. Buchanan | S. Marder | John M. Davis | J. Kane | X. Pi-Sunyer | S. Essock | N. Covell | L. Pogach | D. Kleinberg | N. Schooler | Alexander L Miller | John M Kane | Leonard Pogach | Stephen R Marder | Xavier Pi-Sunyer | J Thomas Bigger | Susan M Essock | Robert W Buchanan | Daniel E Casey | Nina R Schooler | Nancy Covell | Scott Stroup | Ellen M Weissman | Donna A Wirshing | Catherine S Hall | Alan Friedman | David Kleinberg | Steven J Yevich | Bonnie Davis | Steven Shon | D. Wirshing | D. Casey | Bonnie Davis | S. J. Yevich | E. Weissman | C. Hall | Alan Friedman | S. Shon | Stephen Shon | Catherine S. Hall
[1] J. Ananth,et al. Atypical Antipsychotic Drug Use and Diabetes , 2002, Psychotherapy and Psychosomatics.
[2] J. Avorn,et al. Clozapine Use and Risk of Diabetes Mellitus , 2002, Journal of clinical psychopharmacology.
[3] David C. Atkins,et al. Screening and treating adults for lipid disorders. , 2001, American journal of preventive medicine.
[4] M. F. Denisov. Re: Prolactin levels and adverse events in patients treated with risperidone. , 2002, Journal of clinical psychopharmacology.
[5] S. Kennedy,et al. Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[6] Jonathan M. Meyer. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.
[7] W. Glazer,et al. Neuroleptic-induced hyperprolactinemia , 1999, Schizophrenia Research.
[8] C. Tamminga,et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. , 1997, The American journal of psychiatry.
[9] A. Breier,et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. , 2000, Clinical therapeutics.
[10] Jonathan M. Meyer. Novel antipsychotics and severe hyperlipidemia. , 2001 .
[11] S. Marder,et al. Novel antipsychotics: comparison of weight gain liabilities. , 1999, The Journal of clinical psychiatry.
[12] D. Goff,et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. , 2000, The American journal of psychiatry.
[13] H. Meltzer,et al. Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. , 1978, Archives of general psychiatry.
[14] R. Buchanan,et al. A program for treating olanzapine-related weight gain. , 2001, Psychiatric services.
[15] G. Tollefson,et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. , 2001, The Journal of clinical psychiatry.
[16] D. Celermajer,et al. Myocarditis and cardiomyopathy associated with clozapine , 1999, The Lancet.
[17] J. Avorn,et al. Dopamine antagonists and the development of breast cancer. , 2002, Archives of general psychiatry.
[18] N. Ben-Jonathan,et al. Dopamine as a prolactin (PRL) inhibitor. , 2001, Endocrine reviews.
[19] J. Lieberman,et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.
[20] J. Lieberman,et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. , 2003, The American journal of psychiatry.
[21] Alexander L. Miller,et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. , 2002, Schizophrenia bulletin.
[22] T. van Putten. Why do schizophrenic patients refuse to take their drugs? , 1974, Archives of general psychiatry.
[23] D. Allison,et al. Changes in body mass index for individuals with and without schizophrenia, 1987–1996 , 2002, Schizophrenia Research.
[24] S. Marder,et al. The effects of novel antipsychotics on glucose and lipid levels. , 2002, The Journal of clinical psychiatry.
[25] R. Murray,et al. The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis , 2002, Journal of clinical psychopharmacology.
[26] Robert Ross,et al. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. , 2002, Archives of internal medicine.
[27] A. Trontell,et al. Myocarditis and cardiomyopathy associated with clozapine use in the United States. , 2001, The New England journal of medicine.
[28] P. Mortensen. Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients , 1987, Acta psychiatrica Scandinavica.
[29] L. Arvanitis,et al. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.
[30] M. Heo,et al. The distribution of body mass index among individuals with and without schizophrenia. , 1999, The Journal of clinical psychiatry.
[31] R. Dufresne,et al. Olanzapine increases weight and serum triglyceride levels. , 1999, The Journal of clinical psychiatry.
[32] A H Glassman,et al. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.
[33] David M Nathan,et al. Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus , 2002, Annals of Internal Medicine.
[34] R. Tamura,et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.
[35] K. Brismar,et al. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. , 1999, The Journal of clinical psychiatry.
[36] G. L. Noel,et al. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. , 1977, The New England journal of medicine.
[37] G. L’italien,et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. , 2002, Archives of general psychiatry.
[38] J. Bustillo,et al. Differential effect of clozapine on weight: a controlled study. , 1996, The American journal of psychiatry.
[39] P. Goodnick. Ziprasidone: profile on safety , 2001, Expert opinion on pharmacotherapy.
[40] R. Dufresne,et al. Serum triglyceride levels in patients treated with clozapine. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[41] S. Kasper,et al. Review of quetiapine and its clinical applications in schizophrenia , 2000, Expert opinion on pharmacotherapy.
[42] D. Menkes,et al. Cardiotoxicity and Prescription of Thioridazine in New Zealand , 2002, The Australian and New Zealand journal of psychiatry.
[43] H. Hein,et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. , 1998, Circulation.
[44] K. Brismar,et al. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. , 2000, The Journal of clinical psychiatry.
[45] Julie Kreyenbuhl,et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study , 2002, BMJ : British Medical Journal.
[46] P. Doelken,et al. Droperidol Causes a Dose‐dependent Prolongation of the QT Interval , 1994, Anesthesia and analgesia.
[47] F. Arellano,et al. Are Schizophrenia or Antipsychotic Drugs a Risk Factor for Cataracts? , 2000, Epidemiology.
[48] D. Allison,et al. Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.
[49] W. Gsell,et al. Neuroleptic-Induced Hyperprolactinaemia ??? a Case Series , 2006 .
[50] E. Eşel,et al. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients , 2001, Psychoneuroendocrinology.
[51] D. Redelmeier,et al. The treatment of unrelated disorders in patients with chronic medical diseases. , 1998, The New England journal of medicine.
[52] L. Dixon,et al. Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.
[53] Claude Bouchard,et al. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary , 1998 .
[54] R. Aquila. Management of weight gain in patients with schizophrenia. , 2002, The Journal of clinical psychiatry.
[55] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[56] J. Lieberman,et al. Tardive dyskinesia: prevalence, incidence, and risk factors. , 1988, Journal of clinical psychopharmacology.
[57] R. Bland,et al. Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study* , 1991, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[58] Abraham Weizman,et al. Diminished Suicidal and Aggressive Behavior, High Plasma Norepinephrine Levels, and Serum Triglyceride Levels in Chronic Neuroleptic‐Resistant Schizophrenic Patients Maintained on Clozapine , 1998, Clinical neuropharmacology.
[59] U. Wesselmann,et al. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. , 1996, Neuropsychobiology.
[60] J. Lieberman,et al. Prospective study of tardive dyskinesia incidence in the elderly. , 1991, JAMA.
[61] R. Conley,et al. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. , 2001, The American journal of psychiatry.
[62] W. Kannel,et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.
[63] M. Heo,et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.
[64] S. Kapur,et al. Elevation of prolactin levels by atypical antipsychotics. , 2002, The American journal of psychiatry.
[65] G. Remington,et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. , 2001, The American journal of psychiatry.
[66] Robert Rosenheck,et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.
[67] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[68] J. Lieberman,et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. , 2002, The American journal of psychiatry.